Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy
Background Drug-induced interstitial lung disease (DIILD) is a serious adverse event potentially induced by any antineoplastic agent. Whether cancer patients are predisposed to a higher risk of DIILD after receiving immune checkpoint inhibitors (ICIs) is unknown. Methods This study retrospectively assessed the cumulative incidence of DIILD in consecutive cancer patients who received post-ICI antineoplastic treatment within 6 months from the final dose of ICIs. There was also a separate control cohort of 55 ICI-naïve patients with non-small cell lung cancer (NSCLC) who received docetaxel. Results Of 552 patients who received ICIs, 186 met the inclusion criteria. The cohort predominantly comprised patients with cancer of the lung, kidney/urinary tract, or gastrointestinal tract. The cumulative incidence of DIILD in the entire cohort at 3 and 6 months was 4.9% (95% confidence interval [CI] 2.4%–8.7%) and 7.2% (95% CI 4.0%–11.5%), respectively. There were significant differences according to cancer type (Gray’s test, P = .04), with the highest cumulative incidence of DIILD in patients with lung cancer being 9.8% (95% CI 4.3%–18.0%) at 3 months and 14.2% (95% CI 7.3%–23.3%) at 6 months. DIILD was caused by docetaxel in six of these 11 lung cancer patients (54.5%). After matching, the cumulative incidence of docetaxel-induced ILD in patients with NSCLC in the post-ICI setting was higher than that in the ICI-naïve setting: 13.0% (95% CI 3.3%–29.7%) vs 4.3% (95% CI 0.3%–18.2%) at 3 months; and 21.7% (95% CI 7.9%–39.9%) vs 4.3% (95% CI 0.3%–18.2%) at 6 months. However, these were not significant differences (hazard ratio, 5.37; 95% CI 0.64–45.33; Fine–Gray P = .12). Conclusions Patients with lung cancer were at high risk of developing DIILD in subsequent regimens after ICI treatment. Whether NSCLC patients are predisposed to additional risk of docetaxel-induced ILD by prior ICIs warrants further study..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Respiratory research - 25(2024), 1 vom: 10. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kitahara, Yoshihiro [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Docetaxel |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s12931-024-02683-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054341779 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054341779 | ||
| 003 | DE-627 | ||
| 005 | 20240111064651.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240111s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12931-024-02683-8 |2 doi | |
| 035 | |a (DE-627)SPR054341779 | ||
| 035 | |a (SPR)s12931-024-02683-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kitahara, Yoshihiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Background Drug-induced interstitial lung disease (DIILD) is a serious adverse event potentially induced by any antineoplastic agent. Whether cancer patients are predisposed to a higher risk of DIILD after receiving immune checkpoint inhibitors (ICIs) is unknown. Methods This study retrospectively assessed the cumulative incidence of DIILD in consecutive cancer patients who received post-ICI antineoplastic treatment within 6 months from the final dose of ICIs. There was also a separate control cohort of 55 ICI-naïve patients with non-small cell lung cancer (NSCLC) who received docetaxel. Results Of 552 patients who received ICIs, 186 met the inclusion criteria. The cohort predominantly comprised patients with cancer of the lung, kidney/urinary tract, or gastrointestinal tract. The cumulative incidence of DIILD in the entire cohort at 3 and 6 months was 4.9% (95% confidence interval [CI] 2.4%–8.7%) and 7.2% (95% CI 4.0%–11.5%), respectively. There were significant differences according to cancer type (Gray’s test, P = .04), with the highest cumulative incidence of DIILD in patients with lung cancer being 9.8% (95% CI 4.3%–18.0%) at 3 months and 14.2% (95% CI 7.3%–23.3%) at 6 months. DIILD was caused by docetaxel in six of these 11 lung cancer patients (54.5%). After matching, the cumulative incidence of docetaxel-induced ILD in patients with NSCLC in the post-ICI setting was higher than that in the ICI-naïve setting: 13.0% (95% CI 3.3%–29.7%) vs 4.3% (95% CI 0.3%–18.2%) at 3 months; and 21.7% (95% CI 7.9%–39.9%) vs 4.3% (95% CI 0.3%–18.2%) at 6 months. However, these were not significant differences (hazard ratio, 5.37; 95% CI 0.64–45.33; Fine–Gray P = .12). Conclusions Patients with lung cancer were at high risk of developing DIILD in subsequent regimens after ICI treatment. Whether NSCLC patients are predisposed to additional risk of docetaxel-induced ILD by prior ICIs warrants further study. | ||
| 650 | 4 | |a Pneumonitis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Interstitial lung disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Docetaxel |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immune checkpoint inhibitor |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Drug-induced pneumonitis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Inoue, Yusuke |0 (orcid)0000-0001-8075-0597 |4 aut | |
| 700 | 1 | |a Yasui, Hideki |4 aut | |
| 700 | 1 | |a Karayama, Masato |4 aut | |
| 700 | 1 | |a Suzuki, Yuzo |4 aut | |
| 700 | 1 | |a Hozumi, Hironao |4 aut | |
| 700 | 1 | |a Furuhashi, Kazuki |4 aut | |
| 700 | 1 | |a Enomoto, Noriyuki |4 aut | |
| 700 | 1 | |a Fujisawa, Tomoyuki |4 aut | |
| 700 | 1 | |a Funai, Kazuhito |4 aut | |
| 700 | 1 | |a Honda, Tetsuya |4 aut | |
| 700 | 1 | |a Misawa, Kiyoshi |4 aut | |
| 700 | 1 | |a Miyake, Hideaki |4 aut | |
| 700 | 1 | |a Takeuchi, Hiroya |4 aut | |
| 700 | 1 | |a Inui, Naoki |4 aut | |
| 700 | 1 | |a Suda, Takafumi |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory research |d London : BioMed Central, 2001 |g 25(2024), 1 vom: 10. Jan. |w (DE-627)SPR028499905 |w (DE-600)2041675-1 |x 1465-993X |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:1 |g day:10 |g month:01 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12931-024-02683-8 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 1 |b 10 |c 01 | ||